Coccidioidomycosis (Valley Fever, ?VF?) is caused by a soil-dwelling fungus endemic to the southwestern U.S. and central valley in California. The Coccidioides fungus is a dimorphic organism with a mycelial form in soil and spherules (a yeast-like form) in a human host. When soil is disrupted, mycelial spores become airborne and can be inhaled into lungs where they transform into spherules. As spherules burst they release endospores, each of which can grow into a new spherule. Fungal pneumonia may mimic cancer or other community acquired pneumonias (bacterial and viral), but should be recognized as fungal and treated differently. Current diagnostic tests rely on a serologic (antibody) response to fungal antigens. For over 50 years, antigen preparations for detecting antibodies in patients suspected of having Valley Fever have been derived from mycelia which is rich with an antigen called CF (also called CTS-1 or chitinase-1). Serologic assays may be performed by enzyme immunoassay, immunodiffusion or a complement fixation assay to detect antibodies against the fungus. The clinical problem is that approximately 30-50% of patients who are acutely ill initially test sero- negative using current tests, leading to inappropriate treatment. We suggest that one of the reasons for sero-negativity is that mycelial antigen preparations, not spherule antigens, are used for detection of patient antibodies. Since spherules, not mycelia, are what grow in a host, we hypothesize that patients are more likely to make antibodies to antigens predominantly in spherules, the form that grows in the host. In fact, our analysis of the proteomes of Coccidioidal spherules and mycelia demonstrated that the CF (CTS-1, chitinase-1) antigen is highly expressed in mycelia, but not spherules (CF levels are 70-fold higher in mycelia than spherules). Continued proteomic analysis revealed that several other proteins are more highly expressed in spherules than mycelia. The objectives of this grant are to test sero-negative, sero-positive and control patient sera for reactivity and titers against 3 recombinant spherule proteins and to compare titers to commercially available antigen preparations. If sero-negative and sero-positive patient sera are more reactive with spherule antigens alone?or spiked into current diagnostic antigen preparations, this work could translate into a more sensitive, reliable, and consistent antigen preparation for accurate serologic diagnosis of patients with Valley Fever.

Public Health Relevance

Valley Fever is a fungal disease that is estimated to cause > 300,000 infections each year, yet the standard diagnostic approach is using serologic tests that are based on extracts of the soil- dwelling form of the fungus, rather than the human-disease form. The goal of this this research proposal is to extend our findings from the first published Coccidioides proteome to systematically improve antigen preparations used for serologic diagnosis. The primary goal of the project is to increase sensitivity in terms of detecting more individuals who truly have acute disease, and earlier diagnosis in their disease presentation to optimize their care, including avoiding unnecessary antibacterial drugs and administering antifungals when indicated.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI152042-01A1
Application #
10127465
Study Section
Clinical Research and Field Studies of Infectious Diseases Study Section (CRFS)
Program Officer
Ritchie, Alec
Project Start
2020-12-01
Project End
2022-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
1
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Arizona
Department
Type
DUNS #
153665211
City
Scottsdale
State
AZ
Country
United States
Zip Code
85259